TNF and CINCA syndrome: Anti-IL1β antibodies (Anakinra) are prescribed to rheumatoid arthritis and neonatal-onset multisystem inflammatory disease, anti-IL6 receptor antibodies (Tocilizumab) are administered to treat arthritis and anti-TNFα antibodies (Adalimumab) are effective against rheumatoid arthritis, psoriasis and Crohn's disease (41–43).